Sickle Cell Disease: A Brief Update

Sharl Azar, Trisha Wong

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Sickle cell disease (SCD) is an inherited monogenic disease characterized by misshapen red blood cells that causes vaso-occlusive disease, vasculopathy, and systemic inflammation. Approximately 300,000 infants are born per year with SCD globally. Acute, chronic, and acute-on-chronic complications contribute to end-organ damage and adversely affect quantity and quality of life. Hematopoietic stem cell transplantation is the only cure available today, but is not feasible for the vast majority of people suffering from SCD. Fortunately, new therapies are in late clinical trials and more are in the pipeline, offering hope for this unfortunate disease, which has increasing global burden.

Original languageEnglish (US)
Pages (from-to)375-393
Number of pages19
JournalMedical Clinics of North America
Volume101
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Sickle Cell Anemia
Hematopoietic Stem Cell Transplantation
Erythrocytes
Quality of Life
Clinical Trials
Inflammation
Therapeutics

Keywords

  • Hemoglobinopathy
  • Hydroxyurea
  • Iron overload
  • Review
  • Sickle cell anemia
  • Sickle cell disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sickle Cell Disease : A Brief Update. / Azar, Sharl; Wong, Trisha.

In: Medical Clinics of North America, Vol. 101, No. 2, 01.03.2017, p. 375-393.

Research output: Contribution to journalReview article

Azar, Sharl ; Wong, Trisha. / Sickle Cell Disease : A Brief Update. In: Medical Clinics of North America. 2017 ; Vol. 101, No. 2. pp. 375-393.
@article{06ca77723f84486685e1a6d1e3a7c42e,
title = "Sickle Cell Disease: A Brief Update",
abstract = "Sickle cell disease (SCD) is an inherited monogenic disease characterized by misshapen red blood cells that causes vaso-occlusive disease, vasculopathy, and systemic inflammation. Approximately 300,000 infants are born per year with SCD globally. Acute, chronic, and acute-on-chronic complications contribute to end-organ damage and adversely affect quantity and quality of life. Hematopoietic stem cell transplantation is the only cure available today, but is not feasible for the vast majority of people suffering from SCD. Fortunately, new therapies are in late clinical trials and more are in the pipeline, offering hope for this unfortunate disease, which has increasing global burden.",
keywords = "Hemoglobinopathy, Hydroxyurea, Iron overload, Review, Sickle cell anemia, Sickle cell disease",
author = "Sharl Azar and Trisha Wong",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.mcna.2016.09.009",
language = "English (US)",
volume = "101",
pages = "375--393",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Sickle Cell Disease

T2 - A Brief Update

AU - Azar, Sharl

AU - Wong, Trisha

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Sickle cell disease (SCD) is an inherited monogenic disease characterized by misshapen red blood cells that causes vaso-occlusive disease, vasculopathy, and systemic inflammation. Approximately 300,000 infants are born per year with SCD globally. Acute, chronic, and acute-on-chronic complications contribute to end-organ damage and adversely affect quantity and quality of life. Hematopoietic stem cell transplantation is the only cure available today, but is not feasible for the vast majority of people suffering from SCD. Fortunately, new therapies are in late clinical trials and more are in the pipeline, offering hope for this unfortunate disease, which has increasing global burden.

AB - Sickle cell disease (SCD) is an inherited monogenic disease characterized by misshapen red blood cells that causes vaso-occlusive disease, vasculopathy, and systemic inflammation. Approximately 300,000 infants are born per year with SCD globally. Acute, chronic, and acute-on-chronic complications contribute to end-organ damage and adversely affect quantity and quality of life. Hematopoietic stem cell transplantation is the only cure available today, but is not feasible for the vast majority of people suffering from SCD. Fortunately, new therapies are in late clinical trials and more are in the pipeline, offering hope for this unfortunate disease, which has increasing global burden.

KW - Hemoglobinopathy

KW - Hydroxyurea

KW - Iron overload

KW - Review

KW - Sickle cell anemia

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85007578784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007578784&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2016.09.009

DO - 10.1016/j.mcna.2016.09.009

M3 - Review article

C2 - 28189177

AN - SCOPUS:85007578784

VL - 101

SP - 375

EP - 393

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 2

ER -